Core Viewpoint - Thermo Fisher Scientific Inc. has completed the acquisition of Clario Holdings, Inc. for $8.875 billion in cash, with potential additional payments based on performance, enhancing its Laboratory Products and Biopharma Services segment [1] Financial Profile and Synergies - Clario's financial profile is attractive, with expected growth in the high single digits and a contribution of $0.45 to adjusted EPS in the first year post-acquisition [2] - The acquisition is projected to yield a double-digit internal rate of return (IRR) and will be accretive to Thermo Fisher's adjusted operating margin [2] Expected Synergy Realization - Thermo Fisher anticipates realizing approximately $175 million in adjusted operating income from synergies by year five post-acquisition, primarily from revenue synergies due to combined capabilities [3] - The company offers over 2 million products and services across various sectors, including pharmaceutical development and biotechnology research [3]

Illumina FY Conference Summary Company Overview - **Company**: Illumina (NasdaqGS:ILMN) - **Event**: FY Conference at TD Cowen Global Healthcare Conference - **Date**: March 03, 2026 Key Industry Insights - **Product Roadmap**: Illumina showcased its innovation strategy at the AGBT conference, emphasizing the NovaSeq X platform and its capabilities for both high and low capacity applications [4][5] - **TruPath Technology**: Launched as a library prep solution that eliminates traditional library preparation time, allowing for genome sequencing at a cost of $395, which is positioned as the lowest price for high-quality genome sequencing [6][7] - **Spatial Technology**: Illumina is advancing spatial technology to analyze larger tissue samples, which has generated significant customer interest [8][9] - **Competitive Landscape**: Illumina acknowledges competition from Roche, highlighting differences in workflow and pricing models, and expresses confidence in its ability to compete effectively [11][12] Financial Guidance - **Growth Projections**: For 2026, Illumina projects organic growth of 1%-3% excluding China, with a potential upside if the clinical business performs better than expected [30][31] - **Operating Margin**: Targeting a 150 basis point improvement in operating margin, aiming for a 26% operating margin in the near future [31][32] - **Earnings Per Share (EPS)**: Anticipating double-digit growth in EPS, despite headwinds from the SomaLogic acquisition [32] Market Dynamics - **Clinical vs. Research**: The clinical segment is expected to drive growth, particularly in oncology, with a shift towards minimal residual disease (MRD) detection and early cancer detection [43][44] - **Research Challenges**: The research segment faces ongoing pressures, but Illumina remains optimistic about maintaining high single-digit growth in a competitive environment [52] Product Innovations - **Q70 Scores**: Illumina plans to introduce Q70 scores for high sensitivity MRD applications within the next 18 months, which is expected to enhance clinical applications [5][58] - **Protein Prep**: The acquisition of SomaLogic is expected to expand Illumina's capabilities in protein analysis, with a focus on reducing costs and increasing the number of proteins analyzed [64][68] - **BioInsight**: A new initiative aimed at creating large datasets for AI model training in biology, which will be monetized through subscriptions to pharmaceutical companies [92][96] Competitive Positioning - **Roche Comparison**: Illumina believes it is well-positioned against Roche, particularly with the TruPath technology, which offers unique insights and a simpler workflow compared to Roche's offerings [100][101] - **Market Sentiment**: Illumina's leadership expresses confidence in its competitive edge, citing strong R&D and commercial teams as key advantages [108] Conclusion - **Future Outlook**: Illumina is committed to strong growth in a competitive landscape, with a focus on innovation and customer success in both clinical and research applications [108]

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - **Company**: Revvity - **Industry**: Healthcare Diagnostics and Life Sciences Key Points Financial Performance and Guidance - Q4 performance was strong, particularly in reproductive health and newborn screening, with better-than-expected results in China despite market pressures [4][92] - The company maintains a 2%-3% organic growth guidance for 2026, with expectations for margin expansion driven by cost measures implemented in Q4 2025 [5][7] - Positive margin expansion is anticipated to continue into 2027, particularly in the first half [6] Market Conditions - The pharma biotech market is stabilizing, with signs of funding and M&A activity increasing, indicating a shift from cost-cutting to growth and investment [19][21] - The Life Science Solutions segment is expected to see growth, with a focus on reagent sales, which have shown positive growth in four out of five quarters [11][36] - The preclinical market remains weak, but improvements in instrument sales are expected to drive reagent sales higher [10][12] Product Segments - **Immunodiagnostics**: The U.S. market has grown from 5% to 20% of total revenue since the acquisition of Euroimmun, with expectations for further growth driven by autoimmune disease testing [75][77] - **Reproductive Health**: The newborn screening business is expected to continue its outsized growth, supported by new disorder approvals and geographic expansion [104][109] - **Software (Revvity Signals)**: Positioned as a beneficiary of AI developments, with the launch of Synthetica expected to enhance the platform's capabilities [48][49] Competitive Positioning - Revvity has gained market share in the reagent business despite a depressed market, attributed to a strong portfolio and customer stickiness [36][40] - The company is focused on maintaining a competitive edge through continuous product launches and addressing customer needs [55][56] Strategic Initiatives - The company has repurchased 15 million shares over the past two and a half years, indicating confidence in its stock value [120] - Future M&A activities will focus on bolt-on acquisitions that align strategically with Revvity's portfolio [121][124] Challenges and Risks - The guidance for China diagnostics has been conservative, with expectations for a decline in the mid-20s, reflecting ongoing uncertainties in the market [92][93] - The company acknowledges the need to demonstrate consistent performance to gain market confidence, particularly in a recovering environment [125][138] Management Compensation - Management compensation is tied to organic growth, operating margin expansion, and cash flow conversion, with a focus on three-year targets [97][100] Future Outlook - The company aims for significant growth in the Signals business, with expectations to double revenue in the next five years, driven by new product launches and market opportunities [61][70] Conclusion - Revvity is positioned for growth in 2026 and beyond, with a focus on executing its strategic initiatives, expanding its product offerings, and navigating market challenges effectively [138]

Core Viewpoint - The stock price of Waters (WAT) has been on a bearish trend, losing 14% over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with reduced selling pressure, suggesting that bulls may be gaining control [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that after a new low, buying interest emerges to push the stock price up [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is a strong consensus among Wall Street analysts to raise earnings estimates for WAT, which supports the bullish case for the stock [2][7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 1.1%, indicating that analysts expect better earnings than previously predicted [8]. - WAT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]. Conclusion - The combination of the hammer chart pattern and positive earnings estimate revisions enhances the likelihood of a trend reversal for WAT, making it a stock to watch for potential investment opportunities [1][7][10].

Financial Data and Key Metrics Changes - Agilent reported Q1 2026 revenue of $1.8 billion, growing 4.4% on a core basis, with a reported growth of 7% [5][24] - Operating margins were 24.6%, in line with expectations, and down 50 basis points year-over-year due to increased tariff expenses [6][26] - Q1 EPS was $1.36, reflecting a 4% growth, and adjusted for the weather impact, it would have exceeded the midpoint of guidance [6][26] Business Segment Data and Key Metrics Changes - ACG (Agilent CrossLab Group) grew 6%, driven by strong consumables growth and solid performance in services [24] - AMG (Applied Markets Group) grew 4%, led by double-digit performance in spectroscopy, particularly in the semiconductor space [24] - LDG (Life Sciences and Diagnostics Group) grew 3%, slightly below expectations due to weather impact and softness in academia and government [25][59] Market Data and Key Metrics Changes - Pharma growth was 7%, with double-digit growth in biotech, supported by increased funding and M&A activity [17] - The chemicals and advanced materials market grew 9%, with exceptional strength in materials, exceeding 20% growth [18] - The food business declined 4%, but performed better than expected, with strong growth outside of China [19] Company Strategy and Development Direction - The company is focused on enhancing customer intimacy through differentiated service offerings and leveraging the Ignite operating system for operational excellence [7][14] - Agilent aims to capture opportunities from improving end markets, innovative new products, and a multi-pronged replacement cycle [21] - The company is maintaining its expected core growth range of 4%-6% for the full year, with EPS guidance between $5.90 and $6.04 [21][30] Management's Comments on Operating Environment and Future Outlook - Management noted a solid start to the year, with underlying momentum in key markets and expectations for continued growth driven by instrument replacement cycles [16][21] - The company anticipates improved earnings growth through the remainder of the year, supported by increasing volumes and easier tariff comparisons [27] - Management expressed confidence in the ability to navigate the evolving tariff situation and maintain operational resilience [48] Other Important Information - The company experienced a $10 million revenue impact from a winter storm in the U.S., which has mostly been recovered [5][37] - Operating cash flow was $268 million, with investments in CapEx of $93 million and share repurchases of $152 million during the quarter [27] Q&A Session Summary Question: Impact of the snowstorm and expectations for catch-up - Management confirmed the $10 million revenue impact from the snowstorm has mostly been recovered, with a modest impact on margins [35][37] Question: Margin improvement cadence - The second quarter is expected to show a 50 basis point improvement in margins driven by pricing, volume, and Ignite savings [38][39] Question: Drivers for back half growth - Management highlighted strong underlying momentum in pharma and advanced materials as key drivers for growth in the second half [41][42] Question: Tariff assumptions post-Supreme Court ruling - Management stated that current guidance remains unchanged despite the dynamic tariff situation, emphasizing proactive measures taken to mitigate impacts [45][48] Question: Demand trends in capital equipment - Management reported steady demand with no significant deterioration, attributing strong performance to improved CapEx conditions [51][53] Question: M&A environment and appetite - Management expressed a deliberate approach to M&A, focusing on strategic fits without needing transformative deals to achieve growth ambitions [54][55] Question: Performance in the LDG segment - Management noted challenges in the LDG segment due to weather and academic market softness, but expressed optimism for future improvements [58][60]

FINANCIAL RESULTS OVERVIEW 1Q FY2026 February 25, 2026 Thank You for Your Attention Safe Harbor This presentation contains forward- looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertain ...

Core Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) is recognized as one of the top life sciences stocks to buy according to hedge funds, with analysts maintaining positive ratings and price targets [1][3] Financial Performance - The company reported a revenue growth of 3.91% over the past twelve months, achieving total revenue of $44.56 billion [2] - Management provided guidance for organic growth in 2026, forecasting a range of approximately 3–6%, with an initial lean towards the lower end of this range, indicating a cautious but stable outlook [2] Analyst Ratings - Daniel Arias from Stifel Nicolaus maintained a Buy rating on TMO with a price target of $700, highlighting a strong finish to 2025 and a solid Q4 performance [1] - Catherine Schulte from Baird raised the price target from $645 to $653 while maintaining an Outperform rating, reflecting a positive revision of their model following the fourth-quarter announcement [3] Business Segments - Thermo Fisher Scientific Inc. provides high-end life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, serving various markets including academics, biotechnology, government, and pharmaceuticals [4]

Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List, indicating a negative outlook for these companies based on recent earnings estimate revisions Group 1: Company-Specific Insights - Avantor, Inc. (AVTR) provides mission-critical products and services for life sciences industries, with a 9% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Columbus McKinnon Corporation (CMCO) is a scientific and technical instruments company, experiencing a 26% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - The Kraft Heinz Company (KHC) operates in the food and beverages sector, with a 10.3% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2]

Core Insights - Thermo Fisher Scientific Inc. (TMO) has a market capitalization of $202.8 billion and provides a range of life sciences solutions and services [1] - Over the past 52 weeks, TMO shares have declined by 2.4%, underperforming the S&P 500 Index, which gained 14.4% [1] - Year-to-date, TMO stock is down 6.8%, while the S&P 500 has risen by 1.4% [1] Performance Comparison - TMO has also underperformed the State Street Health Care Select Sector SPDR ETF (XLV), which increased by 6.2% over the past 52 weeks [2] - On January 29, TMO shares fell by 2.6% despite reporting better-than-expected Q4 results, with revenue of $12.2 billion and adjusted EPS of $6.57, both exceeding analyst estimates [4] - The company's revenue grew by 7.2% year-over-year, while adjusted EPS increased by 7.7% [4] Financial Outlook - Analysts project TMO's EPS to grow by 7.8% year-over-year to $24.65 for fiscal 2026 [5] - TMO has a strong earnings surprise history, exceeding consensus estimates in the last four quarters [5] - Among 23 analysts covering TMO, the consensus rating is a "Strong Buy," with 18 "Strong Buy," 2 "Moderate Buy," and 3 "Hold" ratings [5] Analyst Ratings and Price Targets - The configuration of analyst ratings has become more bullish, with 16 analysts suggesting a "Strong Buy" rating [7] - JPMorgan Chase & Co. maintained a "Buy" rating on TMO with a price target of $710, indicating a potential upside of 31.5% [7] - The mean price target is $662.95, representing a 22.8% premium, while the highest price target of $750 suggests a potential upside of 38.9% [7]

Q4 & FY 2025 Earnings Earnings Presentation February 11, 2026 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-l ...